Recently, the team of Professor Kang Chunsheng, Professor of Neurosurgery at Tianjin Medical University General Hospital and Deputy Director of the Tianjin Neurological Institute, in collaboration with the Tianjin Key Laboratory of Clinical Multi-omics, published an article titled "Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma" in CNS Neuroscience & Therapeutics. Based on deep-targeted gene sequencing technology, the study confirmed that the ARID1A gene is a key predictive biomarker for glioma and revealed the potential molecular mechanism by which ARID1A mutation promotes glioma progression and mediates temozolomide resistance.
Glioma is the most common primary malignant tumor of the central nervous system. Currently, the treatment effect for glioblastoma (GBM) is not ideal, which may be related to rapid drug resistance after temozolomide (TMZ) treatment and the resulting genetic heterogeneity. Studies have shown that TMZ can activate the DNA mismatch repair mechanism by mediating genome-wide DNA alkylation. Genomic instability caused by abnormal DNA mismatch repair is a key driver of tumorigenesis, recurrence, and chemotherapy resistance. In-depth research into the intrinsic connection between expression profile changes caused by DNA damage repair (DDR) gene mutations and GBM chemotherapy resistance can improve the understanding of glioma treatment resistance.
| Research Methods | Deep-targeted gene sequencing was performed on 228 primary glioma samples, comprehensively analyzing the mutations of 428 genes related to DDR and genomic instability pathways, identifying differentially mutated genes among different grades of glioma, and using I-TASSER for homology modeling to elucidate the protein function changes caused by these gene mutations and their impact on glioma progression. | Research Results | The study shows that the DDR-related gene ARID1A occurs frequently in GBM, significantly more than in low-grade glioma. ARID1A is an important prognostic marker for GBM patients, and its mutation is negatively correlated with the prognosis of glioma patients (p=0.0217), and it has a synergistic effect with NF1; patients with co-mutation of NF1 and ARID1A have a worse prognosis than non-mutated patients (p=0.0137). After ARID1A mutation, the expression levels of Ki-67, pERK, and pMEK1/2 in GBM cells significantly increased, suggesting that ARID1A mutation is an important molecular event in GBM, possibly related to abnormal activation of the Ras/Raf/MEK/ERK pathway.
In the ARID1A KD cell line constructed using siRNA interference, the expression levels of CDK4, CDK6, CCND1, and CDK2 were higher than in the wild type, while the expression levels of the key apoptosis protein BAX and its downstream effector proteins caspase-3/7 significantly decreased, indicating that loss of ARID1A expression may lead to reduced apoptosis and accelerated cell cycle, thereby promoting the malignant phenotype of glioma cells.
Protein structure simulation analysis showed that the high-frequency mutation P16 deletion can alter the ARID1A protein structure and disrupt structural stability. Compared with the wild type, ARID1A-P16 deletion effectively blocked the binding to the SWI/SNF complex core receptor BRG1 protein, weakened the overall stability of the SWI/SNF complex, and altered its intracellular histone modification activity. Furthermore, four models were constructed: ARID1A control, ARID1A KD, ARID1A wild-type overexpression, and ARID1A-P16 deletion overexpression, to analyze the effects of these four changes on the modification and expression of the DDR pathway key functional protein CDKN1A. The results showed that ARID1A is positively correlated with CDKN1A expression; compared with wild-type overexpression, ARID1A-P16 deletion led to reduced CDKN1A expression. In addition, in ARID1A KD and ARID1A-P16 deletion types, acetylation in the H3K27 region of the CDKN1A promoter was significantly reduced, strongly demonstrating that ARID1A may affect CDKN1A transcription through histone acetylation modification, thereby affecting the biological activity of glioma cells. The study also explored the effect of ARID1A mutation on the efficacy of TMZ under in vivo and in vitro conditions. Compared with ARID1A wild type, the GBM apoptosis of the ARID1A KD cell line in response to TMZ treatment was significantly reduced, with obvious clonal growth. At the same time, the ARID1A KD mouse model also showed higher tumor volume and Ki-67 expression than the control, and its growth curve showed more malignant biological characteristics. Intragastric TMZ treatment could not effectively inhibit tumor proliferation. The Kaplan-Meier survival curve showed a significantly shortened median survival (25d vs 31d). To further elucidate the potential mechanism, changes in cyclins and DNA damage repair proteins were compared among ARID1A wild type, ARID1A KD, and ARID1A-P16 deletion versus GBM control cell lines. After treatment with 200 μm TMZ, the expression levels of CDK4, CDK6, CCND1, and CDK2 in the ARID1A-P16 deletion cell line were higher than in the wild type, and DDR proteins (including RAD50) were also affected. These findings confirm the key role of ARID1A mutation in regulating the GBM response to TMZ. | Research Conclusion |
This study reveals that the ARID1A gene is a key predictive biomarker for glioma. After mutation, this gene can alter the stability of the SWI/SNF complex, affecting the transcriptional regulation of glioma. It further leads to an increase in the malignant phenotype of GBM, while also playing a key role in mediating chemotherapy resistance.
